12.03.2024 • News

Kyowa Kirin to Build First US Pharma Operations

Japan-based pharmaceutical company Kyowa Kirin plans to build a $200 million biologics manufacturing center in Sanford, North Carolina, creating 102 jobs. This will be the company’s first North American pharmaceutical manufacturing operation, expected to create 102 jobs.

“Establishing a new center of excellence for biologics manufacturing in North America is a testament to the promising potential we see in our pipeline,” said Paul Testa, Kyowa Kirin’s executive vice president Supply Chain & Manufacturing, North America. “We believe the Sanford facility will become a vital part of our global manufacturing network – helping us train employees, deliver medicines with life-changing value, and support our future growth as a region and as a global business.”

The project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) awarded to Kyowa Kirin North America Manufacturing.

Kyowa Kirin expects to complete the project in four years.

© REB Images/Getty Images
© REB Images/Getty Images

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.